PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Finance

TCI Biotech expands US manufacturing with $26m facility investment

Global biotechnology innovator TCI Biotech announces an investment of approximately $26.225m to expand its existing US manufacturing facility in American Fork, Utah
Finance

Applied Biopharm Consulting secures IP grant to protect AI-driven viral capsid engineering innovations

Irish biotech consultancy Applied Biopharm Consulting has received an IP Start Grant from Enterprise Ireland to develop a formal patent strategy around its AI-powered computational platform for engineered adeno-associated virus vector design
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Manufacturing

Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients

Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

kyron.bio partners with Servier to advance precision glycosylation in antibody therapeutics

The parternship will allow kyron.bio to apply its precision glycoengineering platform to antibody development. Speaking exclusively with Manufacturing Chemist, CEO of kyron.bio, Dr Emilia McLaughlin, explains the importance of the new deal
Finance

CordenPharma Colorado expands peptide development capacity with lease of new lab

Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development
Subscribe now